Live Breaking News & Updates on Juliana Cassataro

Stay updated with breaking news from Juliana cassataro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Covid-19: Latin America defies nationalism and circumstance to develop its own vaccines

Latin American countries not only developed their own covid vaccine prototypes but also rolled them out. Martín De Ambrosio reports on a region taking its first steps towards vaccine security

When the pandemic shook the world in 2020, Argentina, like many countries, went into full lockdown. Juliana Cassataro, a researcher at the National University of General San Martín, wondered what her team could do to help. The answer was obvious for a researcher specialising in oral vaccines: make one.

“From the beginning we planned to make it as a booster we realised that we couldn’t compete with developers with millions and millions of dollars and the support of bigger nation states,” says Cassataro. Her team received a small grant of $100 000 from the Argentine ministry of science in May 2020 to design a prototype based on Cassataro’s specialism: recombinant protein vaccines.

Confidence was not high. Colleagues and politicians told them to give up it was not fea ....

Buenos Aires , Distrito Federal , Estado Do Rio , Estado De Pernambuco , United States , Republic Of , Juliana Cassataro , Elvira Zini , Oxford Astrazeneca , Liz Alvarez Lajonchere , Fidel Castro , Instituto Finlay , Erique Jose Farias Peixoto , Arvac Cecilia Grierson , Brazilian Ministry Of Health , Us National Institutes Of Health , Butantan Institute , National University , Oswaldo Cruz Foundation Fiocruz , World Health Organization , Harvard Th Chan School Of Public Health , General San Mart , South America , President Fidel Castro , Genetic Engineering , Public Health ,

Argentine-developed Covid vax ready to move on to trial phase

Argentine researchers are about to complete de development of the ARVAC Cecilia Grierson Covid-19 vaccine, which is why volunteers are needed for the 2/3 trial phase, it was reported in Buenos Aires. The new drug is expected to be cleared by mid-2023. ....

Buenos Aires , Distrito Federal , Cecilia Grierson , Pablo Cassar , Juliana Cassataro , National Council Of Scientific , National University Of San Mart , Technical Research Conicet , National Administration Of Medicines , Ministry Of Science , Argentine Developed Covid , National Administration , Medical Technology , National Council , Technical Research , National University , San Mart ,